Abstract
BACKGROUND: Recently, there have been several studies that have looked at the association between hOGG1 Ser326Cys polymorphism and esophageal cancer (EC) risk. However, the results of previous reports remain controversial and ambiguous. Thus, we performed a meta-analysis to explore more precisely the association between hOGG1 Ser326Cys polymorphism and the risk of EC. METHODS: A meta-analysis was performed to examine the association between hOGG1 Ser326Cys polymorphism and EC risk. Odds ratio (OR) and its 95% confidence interval (CI) were used for statistical analysis. RESULTS: Our publication search identified a total of 9 studies with 1,875 cases and 3,041 controls. There was no significant associations in all genetic models between hOGG1 Ser326Cys polymorphism and EC observed (OR =1.024, 95% CI: 0.932-1.125 for Cys vs. Ser, P=0.624; OR =1.126, 95% CI: 0.901-1.408 for Cys/Cys vs. Ser/Ser, P=0.296; OR = 0.961, 95% CI: 0.844-1.093 for Ser/Cys vs. Ser/Ser, P =0.540; OR =0.989, 95% CI: 0.874-1.118 for Cys/Cys + Ser/Cys vs. Ser/Ser, P=0.855; OR =1.165, 95% CI: 0.945-1.436 for Cys/Cys vs. Ser/Cys + Ser/Ser, P=0.153). Also, in the stratified analyses by ethnicity and cancer type, no significant association was observed. CONCLUSIONS: This meta-analysis on hOGG1 Ser326Cys polymorphism and the risk of EC suggests there is no statistically significant association between the two. Additional primary studies may be necessary to provide evidence of any significant association between this specific polymorphism and EC.